Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)

Investing

Published: March 9, 2009 7:29 am

Last Updated: March 10, 2020 6:29 pm

We are seeing massive gap-ups this morning in stem cell stocks. President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding. What is interesting here is that this is not really new news other than the timing and the formality. The following prices are as of 8:19 AM EST.

Aastrom Biosciences Inc. (NASDAQ: ASTM) +87% at $0.62
Cytori Therapeutics Inc. (NASDAQ: CYTX) +38% at $3.20
Geron Corp. (NASDAQ: GERN) +29% at $4.99
Neostem Inc. (AMEX: NBS) NOT TRADED
Osiris Therapeutics Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
StemCells Inc. (NASDAQ: STEM) +55% at $2.15
Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57

Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.

JON C. OGG

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.